Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options

Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV).1Nearly nine out of 10 women who die from cervical cancer live in low- and middle-income countries.2For patients living in areas with limited healthcare resources, increasing access to screening and decreasing barriers to sample collection are keys to ultimately preventing this disease.Roche ’s HPV self sampling solution expands access to HPV screening options by enabling patients to privately collect their sample while at a healthcare facility.Basel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of a human papillomavirus (HPV) self sampling solution in countries accepting the CE mark. This new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility, following instructions provided by a healthcare worker. The clinically-validated vaginal sample is analysed with the Roche cobas ® HPV test on a Roche molecular instrument.Screening for human papillomavirus (HPV) can help identify women who are at risk of developing cervical cancer, so that the disease can be found and treated early before it has a chance to develop. There are many drivers that contribute to women not participating in cervical cancer screening programs, including limited access to testing, past experiences, embarrassment and cultural influence...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news